Fexofenadine

Fexofenadine
Clinical data
Trade names	Allegra, others
AHFS/Drugs.com	Monograph
MedlinePlus	a697035
data	EU EMA: by INN; US DailyMed: Fexofenadine; US FDA: Fexofenadine;
Pregnancy; category	AU: B2 ; ;
Routes of; administration	By mouth
Drug class	Antihistamine; H1 receptor antagonist
ATC code	R06AX26 (WHO) ;
Legal status
Legal status	AU: S2 (Pharmacy only) / S4; BR: OTC (Over the counter) ; CA: OTC ; UK: P (Pharmacy medicines) / P/ GSL; US: OTC / Rx-only;
Pharmacokinetic data
Bioavailability	30–41%
Protein binding	60–70%
Metabolism	Hepatic (≤5% of dose)
Elimination half-life	14.4 hours
Excretion	Feces (~80%) and urine (~10%) as unchanged drug
Identifiers
	IUPAC name (±)-4-[1-Hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-butyl]-α, α-dimethyl benzeneacetic acid;
CAS Number	83799-24-0 ;
PubChem CID	3348;
IUPHAR/BPS	4819;
DrugBank	DB00950 ;
ChemSpider	3231 ;
UNII	E6582LOH6V;
KEGG	D07958 ; as HCl: D00671 ;
ChEBI	CHEBI:5050 ;
ChEMBL	CHEMBL914 ;
ECHA InfoCard	100.228.648
Chemical and physical data
Formula	C32H39NO4
Molar mass	501.67 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES O=C(O)C(c1ccc(cc1)C(O)CCCN2CCC(CC2)C(O)(c3ccccc3)c4ccccc4)(C)C;
	InChI InChI=1S/C32H39NO4/c1-31(2,30(35)36)25-17-15-24(16-18-25) 29(34)14-9-21-33-22-19-28(20-23-33)32(37, 26-10-5-3-6-11-26)27-12-7-4-8-13-27/h3-8, 10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36) ; Key:RWTNPBWLLIMQHL-UHFFFAOYSA-N ;
(what is this?) (verify)

Fexofenadinen (ing-gú: Fexofenadine, Fexofenadine hydrochloride) iōng Allegra tíng-tíng ê phín-pâi huàn-bē^[10] sī tsi̍t-tsióng khòng tsoo-tsit-an [en] io̍h-phín, iōng-teh tī-liâu [en] hue-hún-tsìng [en] hām khí-tshìn-mo̍oh [en] tíng-tíng ê kuè-bín-tsìng [en].^[11]

Tsù-kái

↑ "Fexofenadine Use During Pregnancy". Drugs.com. 1 April 2019. 26 July 2020 khòaⁿ--ê.
↑ "Telfast 30mg Film-coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 25 October 2019. 20 June 2021 khòaⁿ--ê.
↑ "Almerg 180 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 20 June 2021 khòaⁿ--ê.
↑ "Fexofenadine Hydrochloride 120 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 22 March 2021. goân-loē-iông tī 2021-06-24 hőng khó͘-pih. 20 June 2021 khòaⁿ--ê.
↑ "Allegra (fexofenadine hydrochloride) tablet, orally disintegrating for oral use Allegra (fexofenadine hydrochloride) tablet, film coated for oral use Allegra (fexofenadine hydrochloride) suspension for oral useInitial U.S. Approval: 1996". DailyMed. 15 December 2008. 13 February 2022 khòaⁿ--ê.
↑ "Allegra Allergy- fexofenadine hydrochloride tablet, coated". DailyMed. 12 February 2022 khòaⁿ--ê.
↑ http://products.sanofi.ca/en/allegra.pdf Archived 2021-01-22 at the Wayback Machine. ^{[bare URL PDF]}
↑ ^8.0 ^8.1 ^8.2 Smith, SM; Gums, JG (July 2009). "Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders". Expert Opinion on Drug Metabolism & Toxicology. 5 (7): 813–22. doi:10.1517/17425250903044967. PMID 19545214.
↑ Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston B, Oosterhuis B, Bjerrum OJ, Rowland M, Garner C (May 2010). "Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability". Eur J Pharm Sci. 40 (2): 125–31. doi:10.1016/j.ejps.2010.03.009. PMID 20307657.
↑ "Fexofenadine - international brand names". Drugs.com. 18 January 2017 khòaⁿ--ê.
↑ Bachert, C (May 2009). "A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis". Clin Ther. 31 (5): 921–44. doi:10.1016/j.clinthera.2009.05.017. PMID 19539095.

Tsham-ua̍t

AeroVironment Switchblade [en] (King-á to bô-jîn-ki)
Pâi-hoâi hîng bú-khì [en] (Pâi-huâi hîng bú-khì/Loitering munition/Pâi-huâi hîng tān-io̍h)
Texas ka-tîng kah pó-hōo ho̍k-bū pōo [en] (Texas Department of Family and Protective Services)
Iryna Venediktova [en]
Kòe-bín-chèng chheng-toaⁿ [en] (Kuè-bín-tsìng tshing-tuañ/List of allergens)

Guā-pōo lên-ket

"Fexofenadine". Drug Information Portal. U.S. National Library of Medicine.
"Fexofenadine hydrochloride". Drug Information Portal. U.S. National Library of Medicine.

[Drugs.com_pregnancy-1] "Fexofenadine Use During Pregnancy". Drugs.com. 1 April 2019. 26 July 2020 khòaⁿ--ê.

[2] "Telfast 30mg Film-coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 25 October 2019. 20 June 2021 khòaⁿ--ê.

[3] "Almerg 180 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 20 June 2021 khòaⁿ--ê.

[4] "Fexofenadine Hydrochloride 120 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 22 March 2021. goân-loē-iông tī 2021-06-24 hőng khó͘-pih. 20 June 2021 khòaⁿ--ê.

[Allegra_FDA_label-5] "Allegra (fexofenadine hydrochloride) tablet, orally disintegrating for oral use Allegra (fexofenadine hydrochloride) tablet, film coated for oral use Allegra (fexofenadine hydrochloride) suspension for oral useInitial U.S. Approval: 1996". DailyMed. 15 December 2008. 13 February 2022 khòaⁿ--ê.

[6] "Allegra Allergy- fexofenadine hydrochloride tablet, coated". DailyMed. 12 February 2022 khòaⁿ--ê.

[7] ttp://products.sanofi.ca/en/allegra.pdf Archived 2021-01-22 at the Wayback Machine. ^{[bare URL PDF]}

[phk09-8] 8.0 ^8.1 ^8.2 Smith, SM; Gums, JG (July 2009). "Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders". Expert Opinion on Drug Metabolism & Toxicology. 5 (7): 813–22. doi:10.1517/17425250903044967. PMID 19545214.

[9] Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston B, Oosterhuis B, Bjerrum OJ, Rowland M, Garner C (May 2010). "Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability". Eur J Pharm Sci. 40 (2): 125–31. doi:10.1016/j.ejps.2010.03.009. PMID 20307657.

[Brands-10] "Fexofenadine - international brand names". Drugs.com. 18 January 2017 khòaⁿ--ê.

[11] Bachert, C (May 2009). "A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis". Clin Ther. 31 (5): 921–44. doi:10.1016/j.clinthera.2009.05.017. PMID 19539095.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[9]

[8]

[10]

[11]